Across the continent , ACE-031, in its 1mg dose , is gaining traction as a novel option for specific brain disorders . Clinical trials in nations such as Germany and la France are assessing its effectiveness on patient outcomes . Agencies throughout Europe are observing the progress of ACE-031, with potential approval expected to rely on the data f